72
Participants
Start Date
August 8, 2022
Primary Completion Date
May 2, 2024
Study Completion Date
May 2, 2024
SAD IMG-004 30mg
Each participant will be randomized to receive a single oral dose of 30mg IMG-004
SAD IMG-004 100mg
Each participant will be randomized to receive a single oral dose of 100mg IMG-004
SAD IMG-004 200mg
Each participant will be randomized to receive a single oral dose of 200mg IMG-004
SAD IMG-004 400mg
Each participant will be randomized to receive a single oral dose of 400mg IMG-004
SAD IMG-004 600mg
Each participant will be randomized to receive a single oral dose of 600mg IMG-004
SAD Placebo 30mg
Each participant will be randomized to receive a single oral dose of 30mg matching placebo
SAD Placebo 100mg
Each participant will be randomized to receive a single oral dose of 100mg matching placebo
SAD Placebo 200mg
Each participant will be randomized to receive a single oral dose of 200mg matching placebo
SAD Placebo 400mg
Each participant will be randomized to receive a single oral dose of 400mg matching placebo
SAD Placebo 600mg
Each participant will be randomized to receive a single oral dose of 600mg matching placebo
MAD IMG-004 50mg
Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
MAD Placebo 50mg
Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
MAD IMG-004 150mg
Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
MAD Placebo 150mg
Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
MAD IMG-004 300mg
Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
MAD Placebo 300mg
Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
FE IMG-004 150mg
A single dose of IMG-004 at 150 mg dose level will be administered to the participants in fed and fasted states
Labcorp Cru, Daytona Beach
Lead Sponsor
Inmagene LLC
INDUSTRY